Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iodine[131I] Metuximab vs Sorafenib vs Chemotherapy for HCC Recurrence Prevention After Liver Transplantation
ChiCTR-IPR-16010204Phase 4Not yet recruiting
- Sponsor
- The Third Medical Center of the Chinese People's Liberation Army General Hospital
- Start
- Dec 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of iodine-131 metuximab, sorafenib and oxaliplatin in hepatocellular carcinoma (HCC) (4 arms), sponsored by The Third Medical Center of the Chinese People's Liberation Army General Hospital. Primary endpoint: Time to recurrence (TTR). Planned start Dec 2016; status: not yet recruiting.
02
Drugs
iodine-131 metuximabsorafeniboxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR-IPR-16010204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16010204.